Stockreport

Crinetics’ Once-Daily Oral Paltusotine Achieved the Primary and All Secondary Endpoints in the Phase 3 PATHFNDR-2 Study in Acromegaly Patients

Crinetics Pharmaceuticals, Inc.  (CRNX) 
Last crinetics pharmaceuticals, inc. earnings: 3/9 04:10 pm Check Earnings Report
PDF 56% of Participants on Paltusotine Achieved IGF-1 =1.0 xULN vs. 5% on Placebo (p Paltusotine was Generally Well-tolerated with No Serious Adverse Events Positive T [Read more]